Benign Prostatic Hyperplasia Therapeutics Market Expected to Reach $9,391.50 Million by 2030

According to a new report published by Allied Market Research, titled, " Benign Prostatic Hyperplasia Therapeutics Market by, Therapeutic Class, Therapy and Region: Global Opportunity Analysis and Industry Forecast, 2021–2030," the global benign prostatic hyperplasia therapeutics market was valued at $5,697.70 million in 2020, and is projected to reach $9,391.50 million by 2030, registering a CAGR of 5.00%.  

Benign prostatic hyperplasia (BPH) is a medical condition in which a male’s prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor. These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostate’s grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.

The growth of the benign prostatic hyperplasia therapeutics market is majorly driven due to rise in prevalence of benign prostatic hyperplasia, rising global geriatric population and soaring awareness related to urological disorders. BPH is a benign condition that does not lead to prostate cancer, though the two problems can coexist. The balance of hormones in body changes as one gets older and may cause the prostate to grow. In addition, the sedentary lifestyle among the older population leads to obesity, which is one of the major risk factor for BPH.

Obesity causes a variety of interventions, including increased intra-abdominal pressure, altered endocrine status, increased sympathetic nervous activity, an increased inflammatory response, and oxidative stress, all of which contribute to the development of BPH. For instance, according to the World Obesity Federation if the current trends continue, it is estimated that approximately 2.7 billion adults will be overweight, over 1 billion affected by obesity, and 177 million adults severely affected by obesity by 2025. Thus, surge in obesity population is expected to drive the growth of the market.

For instance, in December 2021, Veru Inc., an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, announced that the U.S. Food and Drug Administration (FDA) had approved Entadfitm (finasteride and tadalafil) for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).  Furthermore, this combination therapy is anticipated to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. Thus, development of such products significantly boosts the benign prostatic hyperplasia therapeutics market growth.

Moreover, in February 2020, Pharex Health Corporation launched Pharex Tamsulosi in partnership with the Philippine Urological Association (PUA), intended for the management of lower urinary tract symptoms caused by benign prostatic hyperplasia. Thus, such partnership increases the availability of therapeutics and significantly boost the growth of the market.

However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.

By therapeutic class, the market is segmented into alpha blockers, 5- alpha reductase inhibitors, phosphodiesterase-5 inhibitors and others. The alpha blockers segment generated maximum revenue in 2020, accounting $3,337.30 million. The 5- alpha reductase inhibitors segment is expected to witness highest CAGR of 6.50% during the forecast period.

Depending on therapy, the market is differentiated into mono drug therapy, and combination drug therapy. The mono drug therapy segment dominated the market in 2020 with $4,380.10 million and is expected to witness CAGR of 4.70% during the forecast period.

North America accounted for a majority of the global benign prostatic hyperplasia therapeutics market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of BPH, surge in obesity cases due to unhealthy lifestyle, development of new drugs in the pipeline, adoption of improved drug delivery solutions, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in geriatric population, rise in R&D activities and increase in investments in the healthcare sector in the region.

Key Findings Of The Study

• By therapeutic class, alpha blockers were the highest contributor to the market in 2020.
• By therapy type, mono drug therapy segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.
• By region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.